
EACO Corporation Reports Record Quarter Net Sales and Record Quarter Net Income
EACO Corporation reports Record Quarter net sales and Record Quarter income.
Share
Net sales, net income and earnings per share were as follows for the three months ended May 31, 2025 and 2024 (dollars in thousands, except per share information):
The Company had 435 sales employees at May 31, 2025, an increase of 36 employees or 9%, from the prior year quarter. The Company's sales force is divided into sales focus teams (SFT's). The Company had 114 SFT's as of May 31, 2025, four more than the prior year quarter. Management anticipates continued growth in both our headcount and SFT's in fiscal year 2025. The Company believes it continues to gain market share through its local presence business model.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release contains certain forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1955, as amended. These forward-looking statements include, without limitation, statements related to our headcount expansion, growth in market share, and other statement that is not historical information. These forward-looking statements are based on our current expectations and are inherently subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. The potential risks and uncertainties include, but are not limited to, our ability to hire and retain additional qualified employees, our ability to open additional sales offices, and to gain market acceptance for our products, the pricing and availability of our products, the success of our sales and marketing programs, the impact of products offered by our competitors from time to time, and as well as increases to international tariffs. In addition to these factors and any other factors mentioned elsewhere in this news release, the reader should refer as well to the factors, uncertainties or risks identified in EACO's most recent Form 10-K and all subsequent Form 10-Q reports filed by us with the SEC. The forward-looking statements included in this release speak only as of the date hereof, and EACO does not undertake any obligation to update these forward-looking statements to reflect subsequent events or circumstances.
EACO Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(unaudited)
May 31,
2025
2024*
ASSETS
Current Assets:
Cash and cash equivalents
$
3,613
$
843
Restricted cash
10
10
Trade accounts receivable, net
59,875
53,272
Inventory, net
82,780
69,602
Marketable securities, trading
22,063
14,748
Prepaid expenses and other current assets
3,491
3,526
Total current assets
171,832
142,001
Non-current Assets:
Property, equipment and leasehold improvements, net
34,368
35,061
Operating lease right-of-use assets
6,739
7,513
Other assets, net
3,989
3,963
Total assets
$
216,928
$
188,538
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Trade accounts payable
$
37,067
$
28,054
Accrued expenses and other current liabilities
21,494
24,910
Current portion of long-term debt
131
129
Current portion of operating lease liabilities
2,674
2,708
Total current liabilities
61,366
55,801
Non-current Liabilities:
Line of Credit
491
–
Long-term debt
4,116
4,214
Operating lease liabilities
4,222
4,892
Total liabilities
70,195
64,907
Commitments and Contingencies Note 9
Shareholders' Equity:
Convertible preferred stock, $0.01 par value per share; 10,000,000 shares authorized; 36,000 shares outstanding (liquidation value $900)
1
1
Common stock, $0.01 par value per share; 8,000,000 shares authorized; 4,861,590 shares outstanding
49
49
Additional paid-in capital
12,378
12,378
Accumulated other comprehensive income
66
73
Retained earnings
134,239
111,130
Total shareholders' equity
146,733
123,631
Total liabilities and shareholders' equity
$
216,928
$
188,538
* Derived from the Company's audited financial statements included in its Form 10-K for the year ended August 31, 2024 filed with the U.S. Securities and Exchange Commission on November 29, 2024.
Expand
EACO Corporation and Subsidiaries
Condensed Consolidated Statements of Income
(in thousands, except for share and per share information)
(unaudited)
Three Months Ended
May 31,
Nine Months Ended
May 31,
2025
2024
2025
2024
Net sales
$
111,410
$
96,121
$
305,462
$
259,711
Cost of sales
77,337
68,193
214,100
183,184
Gross margin
34,073
27,928
91,362
76,527
Operating expenses:
Selling, general and administrative expenses
21,627
26,314
60,979
61,129
Impairment on termination of lease
-
–
-
3,906
Income from operations
12,446
1,614
30,383
11,492
Other income (expense):
Net gain (loss) on trading securities
277
(24)
761
(45)
Interest and other (expense)
(46)
(44)
(143)
(128)
Other income (expense), net
231
(68)
618
(173)
Income before income taxes
12,677
1,546
31,001
11,319
Provision for income taxes
3,162
362
7,835
2,858
Net income
9,515
1,184
23,166
8,461
Cumulative preferred stock dividend
(19)
(19)
(57)
(57)
Net income attributable to common shareholders
$
9,496
$
1,165
$
23,109
$
8,404
Basic earnings per share:
$
1.95
$
0.24
$
4.75
$
1.73
Diluted earnings per share:
$
1.94
$
0.24
$
4.73
$
1.73
Basic weighted average common shares outstanding
4,861,590
4,861,590
4,861,590
4,861,590
Expand
EACO Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Nine Months Ended
May 31,
2025
2024
Operating activities:
Net income
$
23,166
$
8,461
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization
1,268
1,247
Bad debt expense
203
359
Deferred tax provision
(18)
51
Net unrealized (gain) loss on trading securities
(205)
357
Impairment on termination of lease
–
3,906
Increase (decrease) in cash flow from change in:
Trade accounts receivable
(6,806)
(7,764)
Inventory
(13,178)
(11,139)
Prepaid expenses and other assets
27
98
Operating lease right-of-use assets
774
5,490
Trade accounts payable
6,268
8,043
Accrued expenses and other current liabilities
(3,416)
785
Operating lease liabilities
(704)
(5,501)
Net cash provided by operating activities
7,379
4,393
Investing activities:
Purchase of property, equipment, and leasehold improvements
(575)
(32,527)
Net (purchases) sales of marketable securities, trading
(7,110)
17,466
Net cash used in investing activities
(7,685)
(15,061)
Financing activities:
Borrowings on revolving credit facility
491
–
Repayments on long-term debt
(96)
(94)
Preferred stock dividend
(57)
(57)
Bank overdraft
2,745
3,066
Net cash provided by financing activities
3,083
2,915
Effect of foreign currency exchange rate changes on cash and cash equivalents
(7)
(68)
Net increase (decrease) in cash, cash equivalents, and restricted cash
2,770
(7,821)
Cash, cash equivalents, and restricted cash - beginning of period
853
8,568
Cash, cash equivalents, and restricted cash - end of period
$
3,623
$
747
Supplemental disclosures of cash flow information:
Cash paid for interest
$
143
$
145
Cash paid for income taxes
$
9,213
$
8,276
Expand
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
39 minutes ago
- Associated Press
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. (TEM) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, all dates inclusive (the 'Class Period'), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Tempus AI class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI. The Tempus AI class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (ii) the credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus AI; (iii) Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (iv) AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable 'pass-through payment' via a joint agreement between it, Tempus AI, and Pathos AI, Inc.; and (v) the above issues revealed weakness in core operations and revenue prospects. The Tempus AI class action lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued research report on Tempus AI that raised numerous red flags over Tempus AI's management, operations, and financial reporting. On this news, the price of Tempus AI stock fell more than 19%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus AI common stock during the Class Period to seek appointment as lead plaintiff in the Tempus AI class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Tempus AI class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Tempus AI class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Tempus AI class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]


Business Wire
5 hours ago
- Business Wire
IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million
EVRY, France--(BUSINESS WIRE)--Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs interpretable genomic analyses for academic and private laboratories, announces today its unaudited sales for the first half of 2024. Sales for the first half came to €2,540K, down 34% compared with the first half of 2024 on a like-for-like basis (excluding revenues from the SeqOIA platform), contrary to expectations of weak growth, comparable to that of 2024, as announced by the Company in its press release dated April 29, 2025, on its results for the 2024 financial year. This decline is the result of reduced activity of over 40% on the Institut Pasteur's Mutualized Microbiology platform, linked to the drop in epidemiological sequencing, as well as to the decline in projects carried out on the Evry genomics platform, down by around 31%. This decline is the result of delays in the start-up of two major projects, the first samples of which were received by the company in May, as well as a general slowdown in research projects for academic and hospital customers. The company believes that the second half of the year, with the acceleration of major projects (notably UMBRELLA) and improved funding conditions for public research, should enable the situation to improve from the third quarter onwards. As of June 30 th, available cash, including the remainder on the loan granted to the parent company OncoDNA and repaid over the course of 2025, stood at €2.1m. The company used up €0.9m of cash in the first half of 2025, and at this rate may not have enough cash to ensure its financing for the next 12 months. In this context, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the Company is not maintaining its revenue growth forecasts for 2025. Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: "The first half of the year has been extremely difficult, with both a sharp drop in academic and hospital research projects, linked to a reduction in public research financing, as well as a reduction in the budgets of several biotech companies in a sector affected by the general economic climate. Despite several successes such as the UMBRELLA project, whose operational launch was announced last month, IntegraGen needs to find new sources of funding to be able to ensure the continuity of its operations." Investors are invited to carefully read section 4.2 of the 2024 Management Report on 'Principal risks and uncertainties facing the Company'. Financial results for the first half of 2025 will be published in October. ABOUT INTEGRAGEN IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 40 employees and generated €8.5 million of turnover in 2024. Based in France, IntegraGen is part of the Belgian OncoDNA group present in Spain, UK, Germany and works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).


Business Insider
7 hours ago
- Business Insider
Lotus Technology announces Etika exercised its put option
Lotus Technology (LOT) announced that Etika Automotive exercised its put option on June 30 requiring us to purchase 49% of the equity interests in Lotus Advance Technologies held by Etika pursuant to the Put Option Agreement dated January 31, 2023 between the parties. Lotus UK is currently owned by Geely International and Etika. As announced on April 14 Geely HK exercised a similar put option granted to it by the Company. With Etika having exercised its put option, the Company is expected to acquire 100% of the equity interests of Lotus UK through non-cash transactions based on pre-agreed prices. Upon completion, the Company will gain control over Lotus UK and consolidate its financial results. Lotus UK controls the manufacturing operations of Lotus' sportscars and hyper cars, and Lotus Engineering which provides comprehensive consultancy services to many of the OEMs and Tier 1 suppliers around the world. The acquisition is expected to be completed by 2025. In conjunction with the business combination between the Company and L Catterton Asia Acquisition Corp, a special purpose acquisition company affiliated with L Catterton, a leading global consumer-focused investment firm, the Company and Lotus UK entered into a Put Option Agreement with each of Geely HK and Etika. Pursuant to these agreements, each of Geely HK and Etika was granted the right to require the Company to acquire its equity interest in Lotus UK at a pre-agreed pricing method1 and upon satisfaction of the condition that the total number of vehicles sold by Lotus UK and its subsidiaries shall exceed 5,000 in 2024, with the exercise of such options by Geely HK and Etika not cross-conditioned on one another. As of December 31, 2024, the Put Option Exercise Condition had been satisfied.